Lecrolyn (Sodium Cromoglicate)

Sodium cromoglicate stabilizes mast cells in the conjunctiva and cornea by blocking calcium influx, which prevents the cells from releasing histamine and other inflammatory mediators. By inhibiting this degranulation process, the drug reduces the cascade of allergic inflammation that leads to eye redness, swelling and itching.

The dosing regimen for Lecrolyn is determined by the prescribing clinician based on the severity of the allergic eye condition and patient response. Typically, one or two drops are instilled into the affected eye(s) as directed, but the exact frequency and duration should follow the healthcare professional’s instructions.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision should be made in consultation with a qualified healthcare provider.

To order Lecrolyn, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lecrolyn (sodium cromoglicate) is a mast cell stabilizer, whereas many alternative eye allergy drops are antihistamines or combination antihistamine‑mast cell stabilizers. Sodium cromoglicate primarily prevents mediator release, offering a prophylactic effect, while antihistamines provide rapid symptom relief. Choice of therapy depends on patient preference, severity of symptoms and clinician assessment.

Lecrolyn should be stored at room temperature, away from direct sunlight and moisture. Keep the vial in its original packaging until use, and avoid freezing. If the solution becomes cloudy or discolored, discard it and obtain a new supply.

Lecrolyn is administered as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place the prescribed number of drops into the conjunctival sac. Contact lenses should be removed before instillation and re‑inserted after a suitable waiting period.

Although uncommon, serious adverse reactions can include allergic contact dermatitis of the eyelid or conjunctiva, corneal ulceration or severe keratitis, and sudden loss of vision or intense eye pain. Any of these symptoms require immediate medical evaluation and discontinuation of the product.

Lecrolyn should not be used by individuals with a known hypersensitivity to sodium cromoglicate or any of its excipients. It is also contraindicated in the presence of active ocular infections unless specifically directed by a healthcare professional, and caution is advised in pregnant or breastfeeding women.